PharmaShots | Incisive News in 3 Shots

Subscribe Now

Rallybio

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

Rallybio Receives the CTAs’ Approval for P-II Study of RLYB212 to Treat HPA-1a Alloimmunization and FNAIT

October 30, 2024

Rallybio Partners with Johnson & Johnson on Therapeutic Solutions to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Rallybio Partners with Johnson & Johnson on Therapeutic Solutions to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT...

April 11, 2024

Rallybio Presents P-I Single Ascending Dose Results of RLYB116 for Complement-Mediated Diseases at ICW 2023

Rallybio Presents P-I Single Ascending Dose Results of RLYB116 for Complement-Mediated Diseases at ICW 2023

September 4, 2023

Martin Mackay, CEO of Rallybio, Shares his Thoughts on the Appointment of Jonathan I. Lieber as Chief Financial Officer

Martin Mackay, CEO of Rallybio, Shares his Thoughts on the Appointment of Jonathan I. Lieber as Chief Financial Officer

April 10, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us